Earnings ·
Evaxion A/S reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to $4.8 million…
EVAXEvaxion A/S
Evaxion A/S reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to $4.8 million in the same period last year. Cash and cash equivalents stood at $14.0 million as of June 30, 2026, providing a runway into the second half of 2027. The company announced business updates including upcoming presentations of three-year clinical data for EVX-01 at ESMO Congress 2026 and new preclinical data for EVX-04 and EVX-V1. Evaxion A/S is a clinical-stage biotechnology company developing AI-powered vaccines for cancer and infectious diseases.